EUCTR2013-002451-15-FI进行中（未招募）1 期
A Phase 2b, Randomized, Controlled, Observer-Blind, Multi-Center Study Assessing the Immunogenicity and Safety of GSK Meningococcal ABCWY Vaccine Administered at Different Schedules Compared to GSK Meningococcal group B vaccine, in Healthy Adolescents
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 1,050
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Adolescents from 10-18 years of age, generally in good health, and available for all study visits, who/whose legally acceptable representative has given written informed consent at the time of enrollment. Female subjects of childbearing potential must have a negative urine pregnancy test.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 1050
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Serious, acute, or chronic illnesses. Previous or suspected disease caused by N. meningitidis. Previous immunization with any meningococcal vaccine or Hepatitis A vaccine. Exposure to individuals with clinically proven meningococcal disease or clinical bacterial meningitis without further microbiologic characterization
研究者
相似试验
进行中（未招募）
1 期
Study conducted in healthy adolescents to evaluate safety and antibody response after the administration of different schedules of a vaccine produced by Novartis Vaccines and Diagnostics compared to Novartis Meningococcal group B vaccineand and directed against Meningococcal serogroup A, B, C, Y and W strains.The current study is designed to assess immunological non-inferiority of the MenABCWY vaccine, administered according to 0, 2 month schedule to healthy adolescents 10 to 18 years of age, to those of the licensed rMenB+OMV vaccine (Bexsero™) in terms of hSBA GMTs at one month after the second vaccination.MedDRA version: 19.0Level: PTClassification code 10027202Term: Meningitis bacterialSystem Organ Class: 10021881 - Infections and infestationsEUCTR2013-002451-15-PLGlaxoSmithKline Biologicals SA1,050
进行中（未招募）
不适用
Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY Vaccine Administered to Healthy Adolescents.EUCTR2015-000979-27-Outside-EU/EEAovartis Vaccines and Diagnostics300
进行中（未招募）
不适用
A Phase II, Randomized, Controlled, Observer-Blind, Clinical Study to Evaluate the Humoral and Cell Mediated Immunity and Safety of Two Intramuscular Doses of Fluad® or Agrippal® in Previously Unvaccinated Healthy Subjects Aged 6 to <36 MonthsinfluenzaEUCTR2010-023791-63-DEovartis Vaccines and Diagnostics S.r.l.
进行中（未招募）
1 期
A Phase II, Randomized, Controlled, Observer-Blind, Clinical Study to Evaluate the Humoral and Cell Mediated Immunity and Safety of Two Intramuscular Doses of Fluad® or Agrippal® in Previously Unvaccinated Healthy Subjects Aged 6 to <36 MonthsinfluenzaEUCTR2010-023791-63-BEovartis Vaccines and Diagnostics S.r.l.
进行中（未招募）
不适用
A Phase 2, Randomized, Controlled, Observer-Blind, Multi-Center Study Assessing the Safety and Immunogenicity of One Dose of Novartis' Meningococcal ACWY-CRM Vaccine and GlaxoSmithKline Biologicals' Meningococcal ACWY-TT Vaccine in Healthy ToddlersTo assess the Safety and Immunogenicity of One Dose of Novartis' Meningococcal ACWY-CRM Vaccine and GlaxoSmithKline Biologicals' Meningococcal ACWY-TT Vaccine in Healthy ToddlersMedDRA version: 16.0Level: PTClassification code 10027202Term: Meningitis bacterialSystem Organ Class: 10021881 - Infections and infestationsEUCTR2013-000862-13-ITovartis Vaccines and Diagnostics S.r.l.